Related Experiment Video
Updated: May 13, 2026
06:01
Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time
Published on: July 26, 2024
Antidepressants for functional gastrointestinal disorders in children
Edmund Tan1, Christine H Smith, Ran D Goldman
1Department of Pediatrics, BC Children's Hospital, Vancouver, BC V6H 3V4, Canada.
Canadian Family Physician Medecin De Famille Canadien
|March 15, 2013
Summary
Selective serotonin reuptake inhibitors (SSRIs) are not recommended for treating functional gastrointestinal disorders (FGIDs) in children. Evidence does not support their effectiveness and suggests potential risks, including increased suicidal thoughts in adolescents.
Area of Science:
- Pediatric Gastroenterology
- Child and Adolescent Psychiatry
- Pharmacology
Background:
- Functional gastrointestinal disorders (FGIDs) are complex conditions frequently encountered in pediatric patients.
- Selective serotonin reuptake inhibitors (SSRIs) are sometimes prescribed for FGIDs despite not being indicated for this condition.
Purpose of the Study:
- To evaluate the effectiveness and safety of antidepressants, specifically SSRIs, for treating FGIDs in children and adolescents.
Main Methods:
- Review of existing literature and clinical evidence regarding SSRI use in pediatric FGIDs.
- Analysis of theoretical benefits versus empirical evidence for SSRI efficacy.
- Assessment of safety data, including potential adverse effects like suicidal ideation.
Main Results:
- No conclusive evidence supports the effectiveness of SSRIs for treating FGIDs in pediatric populations.
- Limited large-scale, well-controlled studies exist for SSRI use in pediatric FGIDs.
- Evidence suggests a potential increased risk of suicidal thoughts in adolescents using SSRIs.
Conclusions:
- Current evidence does not support the use of SSRIs for treating FGIDs in children and adolescents.
- The pathogenesis of FGIDs remains largely idiopathic, complicating treatment strategies.
- Healthcare providers should exercise caution due to the lack of proven efficacy and identified safety concerns.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...